FDA: Investigational New Drug Applications; Co-Development of Investigational New Drugs

September 7, 2010

BIO suggests the proposed guidance address dose finding, additive or synergistic efficacy, additive or synergistic safety, drug interactions, special populations, unique toxicities, and study design.